What is the preferred biomarker for the assessment of myocardial necrosis?
The presence of myocardial ischemia is, by definition, universal among patients with acute coronary syndrome (ACS). To support the clinical evaluation of such patients, biomarkers such as serum troponins are frequently tested. While conventional troponins (cTnI and cTnT) are an important foundation for detection of acute myocardial necrosis in the context of chest pain or other symptoms consistent with myocardial ischemia (and are the defining biomarker for the definition of acute myocardial infarction [AMI](1)), these biomarkers are limited by the fact that a substantial proportion of ACS patients have a negative cTn value at presentation, but then have subsequent cTn elevation on later blood draws. Furthermore, a substantial percentage of ACS patients have a cTn value that does not change, even after serial sampling over time. Such latter patients, by definition, do not have MI, but have unstable angina pectoris (UAP). Show
Thus, while outstanding diagnostic tools, cTnI and cTnT have limitations for ACS diagnosis; given the universal presence of myocardial ischemia as a cause of ACS, a biomarker reflective of ischemia, rather than necrosis per se, would theoretically be desirable, and incrementally useful to troponin testing. Such a biomarker of myocardial ischemia has been eagerly sought, but to date, no biochemical standard for detection of myocardial ischemia yet exists. Several candidates have recently been evaluated. Highly Sensitive TroponinTroponins are the gold standard for the diagnosis of acute MI, thus it is not intuitive to assume that they can be used to identify ischemia without frank myocardial necrosis. Nonetheless, a small percentage of the intracellular myocyte cTn is found in the cytosol, and this pool of cTn could theoretically be released by the heart in the absence of complete cardiomyocyte death. While such low-level releases of cTn may be undetectable by conventional assays, recent availability of highly sensitive troponin (hsTn) methods—which have the ability to detect very low concentrations of troponin with exceptionally high precision—has led to the recognition that many patients previously suspected as having UAP actually have measurable levels of hsTn.(2,3) Such patients will now be defined as AMI by recommended consensus guidelines.(1) However, recent studies have demonstrated that hsTn concentrations may be elevated in the absence of documented scarring on magnetic resonance imaging, may change during exercise testing(4) or may elevate following high heart rates induced with transvenous pacing in those without coronary artery disease(5); therefore, it is mechanistically reasonable to consider that hsTn may, in certain cases, reflect myocardial ischemia without irreversible cardiac injury. Whether this is the case remains to be proven conclusively. Ischemia-Modified AlbuminIt is hypothesized that deranged metabolic milieu present in ischemic organs leads to free radical modification of serum albumin as it passes through the oxygen-starved tissues, affecting its ability to bind cobalt at its amino-terminus. These modifications generate measurable amounts of “ischemia modified albumin” (IMA). An assay for detection of this abnormal albumin was developed, and has been evaluated as a tool to detect myocardial ischemia. In pre-clinical studies a very rapid rise of IMA following induced myocardial ischemia was noted(6), and subsequent clinical studies in patients with chest discomfort a low IMA result appeared particularly promising for the confident exclusion of myocardial ischemia when combined with a normal cTn and 12-lead electrocardiogram.(7) Subsequent data have called the accuracy of IMA testing into question(3,8), and the value of the biomarker remains unclear, particularly given its non-specificity for myocardial ischemia. B-type Natriuretic Peptide and N-terminal proBNPB-type natriuretic peptide (BNP) and its amino-terminal pro-peptide equivalent (NT-proBNP) are important cardiac biomarkers widely-used for detection of heart failure (HF), and are well-established prognostic markers in ACS. Importantly, myocardial ischemia may also lead to an increased in ventricular wall stress resulting in release of BNP or NT-proBNP, as demonstrated in studies of exercise tolerance testing, although the extent of change was small.(9) Thus, off-label use of the natriuretic peptides as a diagnostic tool for ACS is also reasonable to consider. As demonstrated by Bhardwaj and colleagues(3), among patients with ACS, those with UAP (defined using a non-highly sensitive cTn assay) had higher concentrations of NT-proBNP than those with non-cardiac causes of chest symptoms; patients with AMI had the highest concentrations. Furthermore, the addition of NT-proBNP was additively useful to cTnT in reclassification analyses for the exclusion of ACS, such that those with low values for both biomarkers had an extremely low likelihood for ACS. A patient who was “double negative” for cTn and natriuretic peptide are thus at very low risk for adverse outcome, and have a very low likelihood for ACS. Despite these results, the tight association between BNP or NT-proBNP and HF makes these markers less specific for myocardial ischemia, and in reclassification analyses, natriuretic peptides did not add to hsTn for the detection or exclusion of ACS. In addition, in another study of low risk patients, BNP was not useful for excluding ACS.(10) Thus, with more widespread use of hsTn, the value of natriuretic peptides for exclusion of myocardial ischemia may be less clear. This does not reduce the prognostic value of these markers in such patients, however. Whole Blood CholineWhole blood choline concentrations have potential promise for the diagnostic evaluation of patients with myocardial ischemia.(11,12) Concentrations of whole blood choline rise in patients with myocardial ischemia, even in settings where no detectable necrosis is present; the origin of choline generation resulting from myocardial ischemia is unclear, but a metabolic alteration within myocytes (from aerobic to anaerobic metabolism) is suspected. An important limitation of prior studies is that hsTn was not used; therefore, it is not clear how many of the patients detected by choline would have been identified using current generation hsTn assays. Large-scale validation of whole blood choline as a biomarker of myocardial ischemia is lacking, and analytical issues with its measurement remain. Unesterified Free Fatty AcidsBlood plasma contains approximately 40 different forms of unesterified free fatty acid (FFAu) chains, and elevated FFAu have been associated with the presence of myocardial ischemia. The mechanism of FFAu release in the context of coronary ischemia is not yet understood; it is hypothesized that ischemia results in increased adipose lipolysis or acute changes in myocardial metabolism. FFAu levels rise rapidly after coronary angioplasty-induced ischemia(13), and two small studies suggested that FFAu may be sensitive clinical markers of coronary ischemia(14,15), elevating before traditional biomarkers of necrosis. More compellingly, a recently developed proprietary assay based on the fluorescent response of 7 FFAu probes had a 75% sensitivity, 72% specificity and a 92% negative predictive value for ACS in patients with chest pain(3); FFAu were equally useful to identify or exclude either UAP or acute MI.Interestingly, the results of testing for FFAu were additive to hsTn for detection of ACS. While the baseline FFAu value was important for diagnosis of ACS, a second measurement added significant information to the baseline value, implying serial sampling of FFAu may be of use in this context. Future analyses of this interesting biomarker class are justified. ConclusionsTo date, no biomarker has been shown to conclusively increase with ischemia alone. Of those that have been evaluated, hsTn and FFAu appear the most promising. Further studies will be necessary to better determine their utility in the assessment of the potential ACS patient. References
Share via: Keywords: Acute Coronary Syndrome, Angina, Unstable, Biomarkers, Myocardial Infarction, Troponin, Troponin I What is the preferred biomarker for diagnosing myocardial infarction?Diagnostic biomarkers
Two well known biomarkers in use for diagnosis of acute myocardial infarction are Creatine-Kinase-MB isoform and Cardiac Troponin. In 2000, Cardiac Troponin replaced CK-MB as the biomarker of choice for diagnosing a myocardial infarction [6].
What is the most specific test indicating myocardial necrosis?Troponin is the recommended test for myocardial necrosis, however there is a marked variance in the diagnostic thresholds among different assays.
Which marker of myocardial necrosis is elevated first?Myoglobin levels
It is released more rapidly from infarcted myocardium than troponin and CK-MB and may be detected as early as two hours after an acute myocardial infarction.
Why is troponin the best biomarker?Among the cardiac biomarkers, troponin has the highest stability in the blood (6 to 10 days) while myoglobin is eliminated from the blood after 24 hours and creatine kinase is eliminated after 36 hours. 4. Troponin is the best diagnostic biomarker in minor cardiac damages, especially unstable angina.
|